Physician profile
Ran Rubinstein
NPI 1477536654
$330,298.96
in general payments reported to CMS, 2019-2025
10 companies · $84K in 2025
The $84K reported for 2025 was more than what 99% of Facial Plastic Surgery providers received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $3,775 · 2021: $8,752 · 2022: $30K · 2023: $120K · 2024: $69K · 2025: $84K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $257K · Travel and Lodging: $12K · Food and Beverage: $4,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $257,175.00 |
| Travel and Lodging | $11,657.97 |
| Food and Beverage | $4,627.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $217,466.67 | 2022-2025 | Botox, Kybella |
| Galderma Laboratories, L.P. | $67,896.40 | 2019-2025 | Dysport |
| Allergan, INC. | $44,337.26 | 2019-2022 | |
| Intersect Ent, INC. | $193.73 | 2019-2021 | |
| Merz North America, INC. | $129.26 | 2019-2023 | Xeomin |
| Acelrx Pharmaceuticals, INC. | $122.08 | 2022 | |
| Stryker Corporation | $68.48 | 2020-2022 | |
| Revance Therapeutics, INC. | $31.25 | 2025 | Daxxify |
| Solta Medical, A Division of Bausch Health US, LLC | $31.15 | 2022-2024 | Fraxel |
| Aerin Medical INC. | $22.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ran Rubinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.